Pancreatic Cancer Research

ResearcherCentral South UniversityActive in the last 2 years

Chaohui Zuo

Matched on ORCID iD 0000-0002-0835-7464; OpenAlex author ID A5068083936. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
34
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 1 paper

Papers 10

  1. Interferon-α and thymosin-α1 plus tislelizumab enhance CD8+ T cell cytotoxicity toward pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.isci.2025.113053↗
  2. Exploring the potential of exosomes in diagnosis and drug delivery for pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ijc.34195↗
  3. Effect of exosomes as drug carriers in chemotherapy of pancreatic cancer. First author DOI 10.11817/j.issn.1672-7347.2023.220439↗
  4. Targeting of pancreatic cancer cells and stromal cells using engineered oncolytic Salmonella typhimurium. Co-author DOI 10.1016/j.ymthe.2021.08.023↗
  5. Exosomal miRNA-1231 derived from bone marrow mesenchymal stem cells inhibits the activity of pancreatic cancer. Last author DOI 10.1002/cam4.2633↗
  6. [Clinical significance of exosomal miR-1231 in pancreatic cancer]. Last author DOI 10.3760/cma.j.issn.0253-3766.2019.01.008↗
  7. Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 / NF-kB and L1CAM activities. Co-author DOI 10.1016/j.pan.2018.02.006↗
  8. Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. Co-author DOI 10.1038/ng.3568↗
  9. Identification of common variants in BRCA2 and MAP2K4 for susceptibility to sporadic pancreatic cancer. Co-author DOI 10.1093/carcin/bgt004↗
  10. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Co-author DOI 10.1038/ng.1020↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Biaoming Xu · 3 shared papers, 2023–2025 · strength 0.87
  2. Wenzhi Tan · 2 shared papers, 2022–2025 · strength 0.40
  3. Shun Deng · 1 shared paper, 2025 · strength 0.25
  4. S Shang · 2 shared papers, 2019 · strength 0.18
  5. Jung‐Joon Min · 1 shared paper, 2022 · strength 0.16
  6. Yu Zhang · 1 shared paper, 2019 · strength 0.09
  7. S L Chen · 1 shared paper, 2019 · strength 0.09
  8. Xu Che · 3 shared papers, 2011–2016 · strength 0.08
  9. Dianke Yu · 3 shared papers, 2011–2016 · strength 0.08
  10. Xiaoping Miao · 3 shared papers, 2011–2016 · strength 0.08
  11. Chen Hsuan Wu · 3 shared papers, 2011–2016 · strength 0.08
  12. Guoliang Jiang · 3 shared papers, 2011–2016 · strength 0.08
  13. Xianjun Yu · 3 shared papers, 2011–2016 · strength 0.08
  14. Dongxin Lin · 3 shared papers, 2011–2016 · strength 0.08
  15. Zhuo Liu · 1 shared paper, 2018 · strength 0.08
  16. Chengfeng Wang · 2 shared papers, 2011–2016 · strength 0.06
  17. Chunyou Wang · 2 shared papers, 2011–2016 · strength 0.06
  18. Jiang Chang · 2 shared papers, 2011–2016 · strength 0.06
  19. Zhaoshen Li · 1 shared paper, 2016 · strength 0.04
  20. Jian Zheng · 1 shared paper, 2016 · strength 0.04
  21. Xudong Huang · 1 shared paper, 2016 · strength 0.04
  22. Xianghong Yang · 1 shared paper, 2016 · strength 0.04
  23. Jun Gao · 2 shared papers, 2011–2013 · strength 0.04
  24. Yi Liu · 1 shared paper, 2013 · strength 0.02
  25. Tingting Wu · 1 shared paper, 2013 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.